General Information of Drug Transporter (DT)
DT ID	DTD0515 Transporter Info
Gene Name	ATP10A
Protein Name	Probable phospholipid-transporting ATPase VA
Gene ID	57194
UniProt ID	O60312
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs12595802
Site of GPD	chr15:25806438 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.4294/1922 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Duloxetine	N.A.	Diabetes Mellitus, Type 2	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.		[ 1]
Duloxetine	N.A.	Major Depressive Disorder	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.		[ 1]
Duloxetine	Drug Info	.	Correlated with the decreased response to duloxetine in people with Depressive Disorder, Major (compare with allele A)		[ 1]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Duloxetine	N.A.	Major Depressive Disorder	Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.		[ 1]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Duloxetine	N.A.	Major Depressive Disorder	Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Duloxetine	N.A.	Major Depressive Disorder	Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.		[ 1]
Genetic Polymorphism	rs12913988
Site of GPD	chr15:25733326 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.3952/1979 (Global)
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Clopidogrel	N.A.	Major Adverse Cardiac Events (mace)	Genotypes AA + AG are associated with increased likelihood of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared to genotype GG.		[ 2]
References
1	GWAS-based machine learning approach to predict duloxetine response in major depressive disorder. J Psychiatr Res. 2018 Apr;99:62-68.
2	Influences of an NR1I2 polymorphism on heterogeneous antiplatelet reactivity responses to clopidogrel and clinical outcomes in acute ischemic stroke patients. Acta Pharmacol Sin. 2019 Jun;40(6):762-768.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.